The promise of preventive health is often a data dashboard without a doctor. It’s a PDF of biomarker results landing in an inbox, flagged in red and yellow, with no clear clinical path forward. Emerald Health, a London-based startup founded in 2024, is betting that the real intervention happens not when the algorithm spots an anomaly, but when a licensed general practitioner can act on it. The company has raised £2.9 million to stitch together clinic-based blood tests, wearable data, AI-generated alerts, and ongoing access to an assigned NHS-trained GP into a single membership service [Tech Funding News, October 2026].
The clinical wedge in preventive care
Emerald’s model is built on a specific clinical insight, one that co-founder and NHS doctor Dan McNally brought to the table. The founders concluded that AI alone lacked the medical nuance to responsibly guide patients, while clinicians, overwhelmed by demand, could not proactively serve everyone [Tech Funding News, January 2026]. Their answer is a bundled service. A member gets two annual full-body screenings at one of more than 50 partner clinics across the UK, testing for over 115 biomarkers [Tech Funding News, January 2026]. The results, alongside data from wearables and health history, feed a centralized dashboard. When the system’s AI flags a trend or outlier, the member doesn’t just get an alert,they get a channel to the GP assigned to their account, who can diagnose, prescribe medication, and refer to private or National Health Service specialists [Tech Funding News, October 2026]. This closed loop is the product’s core hypothesis: that actionable prevention requires clinical authority at the point of decision.
The team behind the pivot
The founding trio came together with backgrounds that map to the service’s three pillars: operations, technology, and clinical rigor. CEO Alexander Badalyan previously co-founded Mashroom, a UK proptech and insurtech startup, bringing experience in scaling regulated consumer services [Tech Funding News, May 2025]. CTO Anton Shchipanov developed software at Revolut, a background in building at the pace and complexity of a fintech giant [Tech Funding News, May 2025]. The clinical anchor is Dr. Dan McNally, an NHS doctor who published London’s first 28-day COVID-19 mortality study and previously advised health-tech companies at consultancy Oliver Wyman [Tech Funding News, May 2025]. The team is rounded out by Head of AI Nazar Beknazarov, who previously trained large language models at AI company Toloka [Tech Funding News, May 2025]. Notably, the venture began as an idea for a premium credit-card product before customer feedback pointed the founders decisively toward health screenings and GP access [Tech Funding News, May 2025].
Funding a capital-intensive rollout
Building a service that includes physical blood draws and salaried clinicians is not a lightweight software endeavor. Emerald’s funding history shows a steady capital build to support this rollout.
| Date | Amount | Lead Investor(s) | Stage |
|---|---|---|---|
| May 2025 | £625,000 | Angel investors including Mart Abramov, Jane Austin | Angel [Tech Funding News, May 2025] |
| January 2026 | $1.2 million | Boost Capital Partners | Pre-Seed [Tech Funding News, January 2026] |
| October 2026 | £1.4 million | Boost Capital Partners (context) | Seed [Tech Funding News, October 2026] |
Total disclosed funding reached £2.9 million by October 2026 [Tech Funding News, October 2026]. The repeated participation of Boost Capital Partners across rounds suggests investor confidence in the capital-intensive model. The funds have ostensibly gone toward expanding the network of testing locations, developing the AI and data platform, and covering the clinical operating costs of providing GP care.
The risks in a regulated landscape
For all its ambition, Emerald’s model introduces several complex challenges that will test its venture-scale thesis. The company is navigating a space with significant regulatory, economic, and behavioral hurdles.
- Clinical liability and scale. The service’s value is its clinical integration, but this also creates a bottleneck. Each assigned GP can only handle so many patients. Scaling the GP team in line with member growth, while maintaining quality and managing malpractice risk, is a fundamental operational constraint. The UK’s General Medical Council oversight adds a layer of regulatory gravity not present in pure software health apps.
- Consumer willingness to pay. The market for premium, out-of-pocket preventive care is still being proven in the UK, especially for a subscription service that sits outside the free-at-point-of-use NHS. Emerald must convince a broad enough segment that early detection and convenient GP access are worth a recurring fee, a behavioral shift that marketing alone may not achieve.
- Data integration depth. The promise of a unified health dashboard hinges on smooth data flow from labs, wearables, and patient-reported history. Any friction or incompatibility here undermines the AI’s ability to generate timely, accurate alerts, potentially returning the service to a disconnected set of tools.
Emerald’s answer to these risks appears to be a focus on high-touch, high-quality service as a differentiator, betting that a superior customer and clinical experience will justify the price and overcome adoption inertia.
The standard of care today
The patient population Emerald is addressing is, broadly, the health-anxious and the proactive,adults seeking more control and earlier insight than the reactive NHS system typically provides. The current standard of care for this group is often fragmented. It might involve paying for a one-off private blood test from a service like Medichecks or Thriva, receiving a report online, and then needing to book a separate appointment with a private GP or navigate NHS waiting lists to discuss concerning results. The burden of synthesis and next steps falls entirely on the patient. Emerald is attempting to productize that entire pathway, from needle to prescription, aiming to reduce the friction that leads many to ignore early warning signs. The next twelve months will be a critical test of whether the market is ready to pay for that integration at scale, and whether the company can hit its reported ambition of reaching one million members [Tech Funding News, October 2026]. Success would mean proving that a venture-backed model can sustainably deliver a higher-touch tier of preventive medicine, not as a luxury for the few, but as a scalable service for the many.
Sources
- [Tech Funding News, May 2025] Ex-Revolut and NHS team launches Emerald with £625K to unite health data into one AI-powered preventive plan | https://techfundingnews.com/exclusive-ex-revolut-and-nhs-team-launches-emerald-with-625k-to-unite-health-data-into-one-ai-powered-preventive-plan/
- [Tech Funding News, January 2026] Exclusive: Emerald closes $2M pre-seed to blend blood testing, AI, and medical care | https://techfundingnews.com/emerald-2m-pre-seed-gp-ai-preventive-health/
- [Tech Funding News, October 2026] Emerald raises £1.4m to scale preventive health platform | https://techfundingnews.com/emerald-raises-1-4m-preventive-health-innovate-uk-boost-capital/
- [LinkedIn, Unknown] Post by Ms Jane Austin | https://www.linkedin.com/posts/msjaneaustin_im-so-honoured-to-be-working-with-alex-and-activity-7329097046911561728-knaT
- [Crunchbase, Retrieved 2026] Alexander Badalyan - CFO and Co-Founder @ Mashroom | https://www.crunchbase.com/person/alexander-badalyan
- [LinkedIn, January 2024] Toloka on LinkedIn: Data labeling for Generative AI and LLM | https://www.linkedin.com/posts/toloka_data-labeling-for-generative-ai-and-llm-activity-7152691240348655617-Gr9m